https://www.selleckchem.com/products/cpypp.html
Angiotensin receptor blockers (ARBs), such as telmisartan, have been postulated to treat Covid-19-induced lung inflammation. This is a parallel-group, randomized, two-arm, open-label, adaptive, multicenter superiority trial with 11 allocation ratio. Participants included patients from 18 years of age hospitalized with Covid-19 with 4 or fewer days since symptom onset enrolled at a university and a community hospital in Buenos Aires, Argentina. Exclusion criteria included prior intensive care unit (ICU) admission and use of ARBs/angiotensi
Like
Comment
Share
